TABLE 2.
Characteristics of the 11 samples from eight patients with detectable SVLs
| Patient (sample no.) | SVLa | BPVLa | CD4 cell count/mm3 | HAARTb |
|---|---|---|---|---|
| 1 (1) | 2.607 | 2.297 | 389 | |
| 2 (1) | 2.907 | 3.239 | 282 | TDF + FTC + ATZ/r |
| 3 (1) | 2.775 | <1.7 | 984 | TDF + FTC + LPV/r |
| 4 (1) | 2.779 | 3.817 | 536 | |
| 4 (2) | 4.349 | 3.724 | 457 | |
| 5 (1) | 6.257 | <1.7 | 237 | TDF + FTC + LPV/r |
| 5 (2) | 5.017 | <1.7 | 159 | TDF + FTC + LPV/r |
| 6 (1) | 2.373 | <1.7 | 651 | ABC + 3TC + LPV/r |
| 7 (2) | 2.981 | <1.7 | 703 | ABC + 3TC + NVP |
| 8 (1) | 2.322 | <1.7 | 782 | AZT + 3TC + LPV/r |
| 8 (2) | 2.344 | <1.7 | 580 | AZT + 3TC + LPV/r |
a
Log number of RNA copies per milliliter.
b
Abbreviations: TDF, tenofovir; FTC, emtricitabine; ATZ/r, atazanavir plus ritonavir; LPV/r, lopinavir plus ritonavir; ABC, abacavir; 3TC, lamivudine; NVP, nevirapine.